Totaligent, Inc. has announced an extension to the target date for the negotiation and execution of definitive agreements related to its proposed acqui-hire transaction with Aetherium Medical. Originally set for March 5, 2026, the new target date is now April 10, 2026. This extension allows both parties additional time to complete negotiations and due diligence. The binding exclusivity period established in the Binding Letter of Intent (LOI) has also been extended through the new target date. The LOI outlines the terms under which Totaligent would acquire Aetherium's team, business plan, intellectual property, and related assets in exchange for equity in Totaligent. The company previously disclosed this transaction in its Current Report on Form 8-K filed on February 12, 2026. The extension is seen as a positive step, providing both companies with the necessary time to finalize the details of the agreement, which could enhance Totaligent's operational capabilities and market position if successfully executed.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.